Graham Pockley, Director and Professor, John van Geest Cancer Research Centre, Nottingham Trent University, CEO, multimmune GmbH
Professor A. Graham Pockley, PhD is the CEO of multimmune GmbH (www.multimmune.com), Munich, Germany. multimmune’s unique and proprietary technology platform is based on the discovery (by Gabriele Multhoff and Claus Botzler) that a cell surface bound form of Hp70 is selectively and widely expressed on the plasma membranes of many tumour entities. multimmune is developing innovative theranostics on the basis of membrane Hsp70 expression by tumour cells, including an autologous NK cell-based therapy (ENKASTIMev) |